Bolt Biotherapeutics (BOLT) Financial Statements & Analysis

Bolt Biotherapeutics (BOLT) Income Statement

Bolt Biotherapeutics reported revenue of $7.70M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 0.1% from $7.69M a year earlier. Bolt Biotherapeutics posted a net loss of $33.38M, compared with a net loss of $63.12M a year earlier. Gross margin was 100.0% and operating margin -450.1%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $5.00K, down 99.7% from the same quarter a year earlier.

Bolt Biotherapeutics Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Bolt Biotherapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2020	FY 2019	FY 2018
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Mar 2021	Dec 2020	Dec 2019	Dec 2018
Revenue & Gross Profit
Revenue	7.70	7.69	7.88	5.73	1.26	0.23	0.23	0.22	0.00
Cost of Revenue	28.53	0.00	61.54	73.12	75.66	40.36	40.36	0.00	0.30
Gross Profit	7.70	7.69	7.88	-67.39	1.26	-40.13	-40.13	0.22	-0.30
Operating Expenses
Research & Development	28.53	57.47	61.54	73.12	75.66	40.36	-	26.00	9.42
Selling, General & Administrative	13.80	18.46	22.53	22.93	18.39	9.06	9.06	5.18	2.21
Operating Expenses	42.33	80.74	84.07	22.93	94.05	9.06	9.06	31.18	11.63
Operating Income	-34.63	-73.05	-76.20	-90.32	-92.79	-49.18	-49.18	-30.97	-11.63
Other Income/Expense
Interest Income	2.50	5.26	7.00	2.22	0.28	0.20	0.20	0.52	0.19
Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00
Other Income/Expense	-1.24	9.93	7.00	2.22	-5.80	-11.55	-11.75	0.48	0.04
Income
Income Before Tax	-33.38	-63.12	-69.20	-88.10	-98.59	-60.73	-60.73	-30.49	-11.59
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.04
Net Income	-33.38	-63.12	-69.20	-88.10	-98.59	-60.73	-60.73	-30.49	-11.59
Net Income - Continuous Operations	-33.38	-63.12	-69.20	-88.10	-98.59	-60.73	-	-30.49	-11.59
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-	-
EBITDA	-33.34	-66.46	-74.34	-86.43	-91.60	-48.57	-48.57	-30.63	-11.33
EBIT	-34.63	-68.24	-76.20	-90.32	-92.79	-	-49.18	-	-
Depreciation & Amortization	1.29	1.78	1.85	1.67	1.19	0.61	0.61	0.34	0.30
Earnings Per Share
Basic EPS	-18.00	-2.00	-37.00	-2.00	-59.00	-2.00	-578.00	-4.00	-6.00
Diluted EPS	-18.00	-2.00	-37.00	-2.00	-59.00	-2.00	-578.00	-4.00	-6.00
Basic Shares Outstanding	1.87	1.91	1.89	1.87	1.66	1.81	0.11	0.40	0.10
Diluted Shares Outstanding	1.87	1.91	1.89	1.87	1.66	1.81	0.11	0.40	0.10

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Bolt Biotherapeutics Financial Statements

What was Bolt Biotherapeutics's revenue in fiscal 2025?

Bolt Biotherapeutics reported revenue of $7.70M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 0.1% from $7.69M a year earlier.

Is Bolt Biotherapeutics profitable?

No. Bolt Biotherapeutics reported a net loss of $33.38M in fiscal 2025. In fiscal 2024 it lost $63.12M.

What is Bolt Biotherapeutics's operating margin?

Bolt Biotherapeutics's operating income was −$34.63M on revenue of $7.70M in fiscal 2025, an operating margin of -450.1%, compared with -949.9% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition